Please login to the form below

Not currently logged in
Email:
Password:

UCART19

This page shows the latest UCART19 news and features for those working in and with pharma, biotech and healthcare.

Cellectis floored by patient death in CAR-T trial

Cellectis floored by patient death in CAR-T trial

The French biotech has another CAR-T therapy in clinical testing - CD19-targeting UCART19 for acute lymphoblastic leukaemia (ALL) - and this is unaffected by the clinical hold, with trials ongoing in ... UCART19 is partnered with Servier and Pfizer.

Latest news

  • Servier cleared to start US trials CAR-T therapy Servier cleared to start US trials CAR-T therapy

    The French pharma company entered the race to develop chimeric antigen receptor therapies (CAR-T) for cancer after it acquired exclusive rights to UCART19 from Cellectis in 2015. ... Early results from the CALM trial have already shown that UCART19 can

  • Cellectis gets FDA nod for 'off-the-shelf' CAR-T trial Cellectis gets FDA nod for 'off-the-shelf' CAR-T trial

    Another allogeneic CAR-T therapy - the CD19-targeting UCART19 - is already in trials in the UK being run by partners Servier and Pfizer. ... Cellectis' UCART19 has shown positive effects in two leukaemia patients, although one suffered an episode of graft

  • Baxalta’s rare blood cancer drug Oncaspar approved in Europe Baxalta’s rare blood cancer drug Oncaspar approved in Europe

    It could also eventually see further competition from Pfizer's collaboration with Servier and Cellectis, should UCART19 - which was successfully used to treat an 11-month-old British girl with incurable,

  • Cellectis gets big pharma partners for CAR-T therapy Cellectis gets big pharma partners for CAR-T therapy

    Pfizer and Servier have joined forces to help Cellectis develop UCART19, which hit the headlines earlier this month when it was used to treat a UK girl dying of cancer. ... Pfizer and Servier will collaborate on a joint clinical development programme for

  • CAR-T cancer therapy passes milestone

    treatment with Cellectis' UCART19 cell product. ... That could be a major competitive advantage over autologous approaches, although it remains to be seen whether UCART19's early success will be backed up in clinical trials due to start

More from news
Approximately 1 fully matching, plus 6 partially matching documents found.

Latest Intelligence

  • Deal Watch November 2015 Deal Watch November 2015

    379. Cellectis. Servier. Option exercise. UCART19, CAR-T allogeneic immunotherapy being tested for chronic lymphocytic leukaemia and acute lymphoblastic leukaemia.

  • Deal Watch table for February 2014 Deal Watch table for February 2014

    915. Cellectis / Servier. Licence. Product candidates for solid tumours, UCART19 (allogenic CAR-T) for leukaemia and lymphomas (6 candidates in total).

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Swordfish Advertising

At Swordfish Advertising, we believe building an effective brand shouldn't be stressful. Don't get us wrong; it takes blood, sweat...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics